Synthesis and characterization of hybrid nanocarrier layered double hydroxide grafted by polyethylene glycol and gemcitabine
Source abstract
Abstract
For the past few years, organic-inorganic hybrid nanocarriers have been widely explored for effective drug delivery and preferable disease treatments. In this article, hydrothermal method was utilized to prepare fine dispersed layered double hydroxide (Mg-Al LDH) suspension. Polyethylene glycol (PEG) was grafted on the surface of LDH lamella in order to improve the dispersibility of LDH. Besides, the anti-cancer drug gemcitabine was grafted on the surface of LDH lamellas through chemical grafting. Hence a novel new type of organic-inorganic hybrid drug delivery system LDH-mPEG-Gemcitabine was obtained. In addition, the siRNA was intercalated into the LDH interlamination by ion exchange method to realize drug and gene co-delivery. The loading capacity of LDH and LDH-mPEG-Gemcitabine was evaluated by agarose gel electrophoresis. The characterization by laser particle size analyzer, TEM, FT-IR, XRD, in vitro cell viability and in vitro drug release demonstrated that LDH-mPEG-Gemcitabine possessed fine dispersibility, uniform morphology and particle size, fine biocompatibility, ideal drug loading and releasing capacity and held great potential to be used as a desired co-delivery system for drug and gene.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Layered Double Hydroxides Synthesis and Applications · Magnesium Oxide Properties and Applications · Mesoporous Materials and Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi, China
Department of Bio-Medical Diagnostics, Jinan Guo Ke Medical Technology Development Co., Ltd, Jinan, Shandong, China
Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin, China
References (36)
Show source-provided references
1. Fujiwara K · J Sci Cancer · 2019 · 125 · 4582
2. 10.1056/NEJMoa150506710.1056/NEJMoa1505067 ↗
3. 10.1016/S1470-2045(17)30279-610.1016/S1470-2045(17)30279-6 ↗
4. 10.1093/jjco/hyq18210.1093/jjco/hyq182 ↗
5. van Driel WJ · N Engl J Med · 2018 · 378 · 1363
6. 10.1016/j.addr.2012.09.02810.1016/j.addr.2012.09.028 ↗
7. 10.3390/pharmaceutics502032910.3390/pharmaceutics5020329 ↗
8. 10.2174/138527281966614080620035510.2174/1385272819666140806200355 ↗
9. 10.1002/adhm.20140011610.1002/adhm.201400116 ↗
10. 10.1016/j.jcrysgro.2014.01.05610.1016/j.jcrysgro.2014.01.056 ↗
11. 10.1021/la303957y10.1021/la303957y ↗
12. 10.1002/smll.20120155810.1002/smll.201201558 ↗
13. 10.1039/b718745a10.1039/b718745a ↗
14. 10.1021/am101235810.1021/am1012358 ↗
15. 10.1021/nn201390410.1021/nn2013904 ↗
16. 10.1002/adma.20070172610.1002/adma.200701726 ↗
17. 10.1039/b821416f10.1039/b821416f ↗
18. 10.1021/nn101511710.1021/nn1015117 ↗
19. 10.1039/b106465g10.1039/b106465g ↗
20. 10.1126/science.115758110.1126/science.1157581 ↗
21. 10.1016/S0378-5173(01)00629-910.1016/S0378-5173(01)00629-9 ↗
22. 10.1002/1521-3773(20001117)39:22<4041::AID-ANIE4041>3.0.CO;2-C10.1002/1521-3773(20001117)39:22<4041::AID-ANIE4041>3.0.CO;2-C ↗
23. 10.1016/j.jconrel.2013.03.03410.1016/j.jconrel.2013.03.034 ↗
24. 10.3390/ijms1505740910.3390/ijms15057409 ↗
25. 10.1016/j.cej.2009.08.00310.1016/j.cej.2009.08.003 ↗
26. 10.1002/smtd.20190034310.1002/smtd.201900343 ↗
27. 10.1016/j.jconrel.2020.12.04110.1016/j.jconrel.2020.12.041 ↗
28. 10.1016/j.biomaterials.2013.12.09510.1016/j.biomaterials.2013.12.095 ↗
29. 10.1016/j.clay.2009.11.03210.1016/j.clay.2009.11.032 ↗
30. 10.1016/j.eurpolymj.2021.11028610.1016/j.eurpolymj.2021.110286 ↗
31. 10.1039/c3tb20831a10.1039/c3tb20831a ↗
32. 10.1016/j.jcis.2018.03.00610.1016/j.jcis.2018.03.006 ↗
33. 10.1016/j.canlet.2020.11.01310.1016/j.canlet.2020.11.013 ↗
34. 10.2147/IJN.S26667610.2147/IJN.S266676 ↗
35. 10.1021/ja056652a10.1021/ja056652a ↗
36. 10.1007/s12209-016-2710-210.1007/s12209-016-2710-2 ↗